Beauchamp Cynthia L, Beauchamp George R, Stager David R, Brown Melissa M, Brown Gary C, Felius Joost
Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, USA.
J AAPOS. 2006 Oct;10(5):394-9. doi: 10.1016/j.jaapos.2006.06.004.
Cost-utility analysis evaluates the cost of medical care in relation to the gain in quality-adjusted life years (QALYs). Our purpose was to develop a cost model for surgical care for adult strabismus, to estimate the mean cost per case, to determine the associated gain in QALYs, and to perform cost-utility analysis.
A cost model incorporated surgery, pre- and postoperative care, and a mean of 1.5 procedures per patient. The gain in QALYs was based on the improvement of utility on a scale from 0 (death) to 1 (perfect health). Utility was measured through physician-conducted interviews employing a time tradeoff question (seeking to estimate the portion of life expectancy a patient would be willing to trade for being rid of disease and associated effects). The interviews were conducted before and 5 to 8 weeks after surgery in 35 strabismic patients (age 19-75 years).
The cost model resulted in an estimated total cost of 4,254 dollars per case. A significant improvement of utility was found: 0.96 +/- 0.11 postoperatively versus 0.85 +/- 0.20 preoperatively (p = 0.00008). Based on the mean life expectancy (36.0 years) of these patients, and discounting outcomes and costs by 3% annually, this resulted in a mean value gain of 2.61 QALYs after surgery and a cost-utility for strabismus surgery of 1,632 dollas/QALY.
In the United States, treatments <50,000 dollars/QALY are generally considered "very cost-effective." Strabismus surgery in adults falls well within this range.
成本效用分析评估医疗护理成本与质量调整生命年(QALY)增益之间的关系。我们的目的是建立一个成人斜视手术护理的成本模型,估计每例手术的平均成本,确定相关的QALY增益,并进行成本效用分析。
成本模型纳入了手术、术前和术后护理,以及每位患者平均1.5次手术。QALY的增益基于效用从0(死亡)到1(完美健康)的改善。效用通过医生进行的访谈来测量,采用时间权衡问题(旨在估计患者为摆脱疾病及相关影响而愿意牺牲的预期寿命比例)。对35例斜视患者(年龄19 - 75岁)在手术前以及手术后5至8周进行了访谈。
成本模型得出每例手术的估计总成本为4254美元。发现效用有显著改善:术后为0.96±0.11,术前为0.85±0.20(p = 0.00008)。基于这些患者的平均预期寿命(36.0岁),并按每年3%对结果和成本进行贴现,这导致手术后平均QALY增益为2.61,斜视手术的成本效用为1632美元/QALY。
在美国,每QALY成本低于50000美元的治疗通常被认为“非常具有成本效益”。成人斜视手术完全在这个范围内。